Obstetrics & Gynaecology

Top Medical News
Fezolinetant reduces hot flashes in menopausal women
Elaine Soliven, 3 days ago
Treatment with fezolinetant significantly reduced the frequency and severity of vasomotor symptoms (VMS), particularly hot flashes, in women during their menopausal phase, according to the SKYLIGHT 1* trial presented at ACOG 2022.
Salt iodination insufficient to boost iodine status in pregnant women
4 days ago
Despite policy advancement and nutritional monitoring, salt iodination seems to be an insufficient measure to provide the adequate level of iodine to pregnant women, reports a recent meta-analysis.
Antidepressant exposure in pregnancy not a risk factor for neonatal seizures, epilepsy
Jairia Dela Cruz, 4 days ago
In pregnant women, the use of serotonergic antidepressants does not appear to put babies at risk of developing seizures or epilepsy, as reported in a study.
Once-daily, low-dose elagolix reduces HMB in premenopausal women with uterine fibroids
Elaine Soliven, 4 days ago
Once-daily (QD) administration of low-dose elagolix 150 mg led to significantly reduced heavy menstrual bleeding (HMB) in premenopausal women with uterine fibroids, according to a study presented at ACOG 2022.
Oocyte microinjection device allows more efficient intracytoplasmic sperm injection
Jairia Dela Cruz, 5 days ago
A group of Australia-based researchers has developed a novel device that makes intracytoplasmic sperm injection (ICSI) a less technically demanding procedure, reducing dependence on the experience level of embryologists and, in turn, dramatically improving fertilization success.
Relugolix combo improves uterine fibroid symptoms regardless of fibroid location
Stephen Padilla, 17 May 2022
Combination therapy with relugolix (once daily relugolix 40 mg, estradiol 1 mg, norethindrone acetate 0.5 mg) leads to improvement in heavy menstrual bleeding (HMB) and in other uterine fibroid (UF)-related symptoms independent of the location of the largest fibroid, results of a recent study have shown.
Pelvic floor dysfunction in women warrants further attention
Audrey Abella, 17 May 2022
There appears to be a dearth of evidence on the management of nonrelaxing pelvic floor dysfunction (PFD), a debilitating condition characterized by tension of the pelvic floor muscles that frequently leads to pelvic pain, according to data presented at ACOG 2022.
Special Reports
Management of recurrent implantation failure during the COVID-19 pandemic
Dr. Ameet Patki, Dr. Prakash Mayandi, 22 Mar 2022
Recurrent implantation failure (RIF) refers to the failure to achieve a clinical pregnancy after three in vitro fertilization (IVF) attempts with at least four good-quality embryos. RIF leaves couples frustrated and desperate for answers and is challenging for clinicians to handle, compounded by the impact of the COVID-19 pandemic restrictions. Two experts, Dr Ameet Patki, Medical Director of Fertility Associates Mumbai and Hon Assoc Prof at KJ Somaiya Medical College & Hospital, India, and Dr Prakash Mayandi, Metro IVF Fertility Centre, Kuala Lumpur, Malaysia, weigh in with their views on managing RIF during the COVID-19 pandemic.
Product Highlight - Evenity
01 Dec 2021
Romosozumab 105 mg/1.17 mL soln for inj
The changing treatment landscape for premenopausal women with advanced breast cancer: Focus on ribociclib
Dr. Wong Seng Weng, Dr. Lee Guek Eng, 19 Mar 2021
In Singapore, advanced breast cancer (aBC) is the leading cause of cancer death in women 30–49 years of age. For premenopausal women diagnosed with hormone receptor (HR)-positive, HER2-negative BC, cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors provide new hope. Currently, ribociclib is the only CDK4/6 inhibitor studied in the first-line setting for premenopausal women with HR+/HER2- aBC, in the phase III MONALEESA-7 trial. Two experts, Dr Wong Seng Weng, Medical Director & Consultant Medical Oncologist at The Cancer Centre, Paragon Medical & Mount Elizabeth Novena Specialist Centre, and Dr Lee Guek Eng, Senior Consultant & Specialist in Medical Oncology at Icon Cancer Centre and Program Director of the Young Women Cancer Program, weigh in with their views on managing premenopausal women with aBC.
Acute diarrhoea is the second leading cause of death
in children aged younger than 5 years, accounting for
approximately 1.
01 Sep 2020
Acute diarrhoea is the second leading cause of deathin children aged younger than 5 years, accounting forapproximately 1.9 million deaths worldwide each year;however, diarrhoea is a preventable and treatable condition.In Malaysia, acute gastroenteritis accounts for about 1.3%of all deaths in children aged younger than 5 years annually.Diarrhoea is defined as the passage of three or more looseor watery stools within 24 hours, and it may be clinicallycategorised as either acute watery diarrhoea (AWD), acutebloody diarrhoea, persistent diarrhoea or diarrhoea withsevere malnutrition.
Expert consensus: Patient profile should guide antihistamine choice in primary care setting
10 Dec 2019
Oral H1-antihistamines are the initial treatment of choice for allergic rhinitis (AR) and chronic urticaria in the primary care setting. However, in a diverse population of patients with AR and urticaria, primary care physicians are faced with the challenge of prescribing the best therapy amid a wide armamentarium of antihistamines available.
Gangliosides and cognition: An appraisal of the evidence
01 Sep 2018

Gangliosides and docosahexaenoic acid (DHA) play critical roles in early childhood brain development. 

SNPs likely to improve breast cancer risk prediction
Dr Joslyn Ngu, 04 Dec 2017

Incorporating polygenic risk scores based on 18 SNPs (single nucleotide polymorphisms) into risk stratification for breast cancer will improve screening results, says an expert.

Conference Reports
Fezolinetant reduces hot flashes in menopausal women
Elaine Soliven, 21 May 2022
Treatment with fezolinetant significantly reduced the frequency and severity of vasomotor symptoms (VMS), particularly hot flashes, in women during their menopausal phase, according to the SKYLIGHT 1* trial presented at ACOG 2022.
Once-daily, low-dose elagolix reduces HMB in premenopausal women with uterine fibroids
Elaine Soliven, 20 May 2022
Once-daily (QD) administration of low-dose elagolix 150 mg led to significantly reduced heavy menstrual bleeding (HMB) in premenopausal women with uterine fibroids, according to a study presented at ACOG 2022.
Relugolix combo improves uterine fibroid symptoms regardless of fibroid location
Stephen Padilla, 17 May 2022
Combination therapy with relugolix (once daily relugolix 40 mg, estradiol 1 mg, norethindrone acetate 0.5 mg) leads to improvement in heavy menstrual bleeding (HMB) and in other uterine fibroid (UF)-related symptoms independent of the location of the largest fibroid, results of a recent study have shown.
Pelvic floor dysfunction in women warrants further attention
Audrey Abella, 17 May 2022
There appears to be a dearth of evidence on the management of nonrelaxing pelvic floor dysfunction (PFD), a debilitating condition characterized by tension of the pelvic floor muscles that frequently leads to pelvic pain, according to data presented at ACOG 2022.
Levonorgestrel IUD  staves off heavy menses in obese nulliparous women
Elvira Manzano, 17 May 2022
The use of an intrauterine device (IUD) containing levonorgestrel 52 mg cuts heavy menses in obese nulliparous women in a phase III study.
ED-dispensed mifepristone plus misoprostol improves access to early pregnancy loss care
Jairia Dela Cruz, 16 May 2022
Administering mifepristone and misoprostol in the emergency departments (EDs) appears to be effective, increasing the availability of early pregnancy loss medical management services to women during the COVID-19 pandemic in the US, as shown in a study presented at the 2022 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting.
COVID-19 vaccine for pregnant women: The data so far
Stephen Padilla, 16 May 2022
Acceptance rates of COVID-19 vaccines have remained unchanged among unvaccinated pregnant women following national recommendations, with nearly one-third of patients seeing the vaccine as something harmful to their pregnancy, according to a study.